



**Recommendation to the Cancer Systemic Therapy Policy Committee (CSTPC)
from Capital District Health Authority/*Cancer Care Nova Scotia***

Guidelines for the Role of Azacitidine in Myelodysplastic Syndrome (MDS)

Approved Use:

Azacitidine: As a **single agent** for the treatment of patients not eligible for hematopoietic stem cell transplantation (SCT) with intermediate -2 and high risk MDS and AML with 20-30% blasts and multi-lineage dysplasia.

- This policy recommendation represents a **new guideline document** and a restriction of azacitidine for patients not eligible for SCT with intermediate -2 and high risk MDS and AML with 20-30% blasts and multi-lineage dysplasia.